Research

Decoding ERK Signaling Dynamics to Improve Therapies for KRAS-Mutated Cancers

We investigate how cancer cells dynamically process signals through the MAPK/ERK pathway in the presence of KRAS mutations. Using fluorescent biosensors, live-cell imaging, and single-cell analysis, we uncover how KRAS mutations distort ERK activity patterns and collective signaling waves that shape cell survival, proliferation, and drug response. We study how next-generation KRAS inhibitors modulate these dynamics and why resistance frequently emerges. By integrating experimental data with computational modeling, we identify drug combinations that specifically target altered signaling behaviors. Ultimately, we aim to enhance the effectiveness of KRAS-targeted therapies and develop biomarkers that capture signaling dynamics in clinically relevant samples.

Targeting ERK Survival Waves to Boost Chemotherapy Effectiveness

We investigate how dying tumour cells transmit protective ERK signalling waves that help neighbouring cells resist chemotherapy. Using fluorescent biosensors, automated live-cell imaging, and single-cell analysis, we quantify how apoptosis triggers these collective ERK activation events across multiple cancer types and treatments. We dissect the secreted factors and signalling pathways that enable ERK waves to propagate, identifying molecular nodes that can be selectively blocked. By combining chemotherapies with inhibitors of ERK wave propagation, we aim to enhance cell killing and overcome community-driven chemoresistance. Finally, we validate these combinations in patient-derived organoids to establish a translational framework for improving therapeutic response across diverse cancers.

Page updated

Google Sites

Report abuse